Does treatment of intestinal helminth infections influence malaria? Background and methodology of a longitudinal study of clinical, parasitological and immunological parameters in Nangapanda, Flores, Indonesia (ImmunoSPIN Study)

• Main Authors: Sutanto Inge, Wahyuni Sitti, Djuardi Yenny, Wibowo Heri, Uh Hae, Ariawan Iwan, Lell Bertrand, Wammes Linda J, Hamid Firdaus, Prasetyani Margaretta A, Wiria Aprilianto E, May Linda, Luty Adrian JF, Verweij Jaco J, Sartono Erliyani, Yazdanbakhsh Maria, Supali Taniawati
• Format: Article
• Language: English
• Published: BMC 2010-03-01
• Series: BMC Infectious Diseases
• Online Access: http://www.biomedcentral.com/1471-2334/10/77

<p>Abstract</p> <p>Background</p> <p>Given that helminth infections are thought to have strong immunomodulatory activity, the question whether helminth infections might affect responses to malaria antigens needs to be addressed. Different cross-sectional studies using diverse methodologies have reported that helminth infections might either exacerbate or reduce the severity of malaria attacks. The same discrepancies have been reported for parasitemia.</p> <p>Methods/Design</p> <p>To determine the effect of geohelminth infections and their treatment on malaria infection and disease outcome, as well as on immunological parameters, the area of Nangapanda on Flores Island, Indonesia, where malaria and helminth parasites are co-endemic was selected for a longitudinal study. Here a Double-blind randomized trial will be performed, incorporating repeated treatment with albendazole (400 mg) or placebo at three monthly intervals. Household characteristic data, anthropometry, the presence of intestinal helminth and <it>Plasmodium spp </it>infections, and the incidence of malaria episodes are recorded. <it>In vitro </it>cultures of whole blood, stimulated with a number of antigens, mitogens and toll like receptor ligands provide relevant immunological parameters at baseline and following 1 and 2 years of treatment rounds. The primary outcome of the study is the prevalence of <it>Plasmodium falciparum </it>and <it>P. vivax </it>infection. The secondary outcome will be incidence and severity of malaria episodes detected via both passive and active follow-up. The tertiary outcome is the inflammatory cytokine profile in response to parasite antigens. The project also facilitates the transfer of state of the art methodologies and technologies, molecular diagnosis of parasitic diseases, immunology and epidemiology from Europe to Indonesia.</p> <p>Discussion</p> <p>The study will provide data on the effect of helminth infections on malaria. It will also give information on anthelminthic treatment efficacy and effectiveness and could help develop evidence-based policymaking.</p> <p>Trial registration</p> <p>This study was approved by The Ethical Committee of Faculty of Medicine, University of Indonesia, ref:194/PT02.FK/Etik/2006 and has been filed by ethics committee of the Leiden University Medical Center. Clinical trial number:ISRCTN83830814. The study is reported in accordance with the CONSORT guidelines for cluster-randomized studies.</p>